Sakharosnizhayushchiy effekt flozinov po sravneniyu s preparatami sul'fonilmocheviny u patsientov s sakharnym diabetom 2 tipa


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Until recently, the sulfonylureas (SM), despite their disadvantages (increased risk of hypoglycaemia and weight gain), remain the drugs of choice of the second - and even, in some cases, the first-line treatment of patients with type 2 diabetes mellitus (DM2) due to their availability. Each new class of tablet hypoglycemic drugs is considered in terms of glucose-lowering effectiveness, and sulfonylureas, first of all, are drugs for the comparison. In recent years, the results of the three direct comparative relatively long-term studies of a new class of anti-diabetic drugs - sodium-glucose cotransporter 2 (SGLT2) inhibitors - and sulfonylureas were published. All three studies have demonstrated a statistically significant benefit of SGLT2 inhibitors compared to sulfonylureas. This review is devoted to the results of these studies. It revaluates the role of sulfonylureas in the treatment of DM2 and discusses the prospect of new possibilities of therapy, taking into account the emergence of a new class of drugs - SGLT2 inhibitors with a comprehensive activity profile.

Full Text

Restricted Access

About the authors

G. R Galstyan

References

  1. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., FerranniniE., Nauck M., Peters A.L., Tsapas A., Wender R., Matthews D.R. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-79.
  2. Rosenstock J., Hassman D.R., Madder R.D., Brazinsky S.A., Farrell J., Khutoryansky N., Hale P.M. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care. 2004;27(6):1265-70.
  3. Raskin P, Klaff L., McGill J., South S.A., Hollander P., Khutoryansky N., Hale PM. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care. 2003;26(7):2063-68.
  4. Buse J.B., Rosenstock J., Sesti G., Schmidt W.E., Montanya E., Brett JH, Zychma M., Blonde L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47.
  5. Hemmingsen B., Schroll J.B., Wetterslev J., Gluud C., Vaag A., Sonne D.P, Lundstrom L.H., Almdal T. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ. Open. 2014;2(3):E162-75.
  6. Ceriello A., Johns D., Widel M., Eckland D.J., Gilmore K.J., Tan M.H. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care. 2005;28(2):266-72.
  7. Ferrannini E., Fonseca V., Zinman B., Matthews D., Ahren B., Byiers S., Shao Q., Dejager S. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes. Metab. 2009;11(2):157-66
  8. Arechavaleta R., Seck T., Chen Y., Krobot K.J., O'Neill E.A., Duran L., Kaufman K.D., Williams-Herman D., Goldstein B.J. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes. Metab. 2011;13(2):160-8.
  9. Arjona Ferreira J.C., Marre M., Barzilai N., Guo H., Golm G.T., Sisk C.M., Kaufman K.D., Goldstein B.J. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care. 2013;36(5):1067-73.
  10. Hartley P., Shentu Y., Betz-Schiff P., Golm G.T., Sisk C.M., Engel S.S., Shankar R.R. Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial. Drugs Aging. 2015; 32(6):469-76.
  11. Nauck M.A., Meininger G., Sheng D., Terranella L., Stein P.P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, doubleblind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194-205.
  12. Göke B., Gallwitz B., Eriksson J., Hellqvist A., Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract. 2010;64(12):1619-31.
  13. Matthews D.R., Dejager S., Ahren B., Fonseca V., Ferrannini E., Couturier A., Foley J.E., Zinman B. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes. Metab. 2010;12(9):780-89.
  14. Seck T., Nauck M., Sheng D., Sunga S., Davies M.J., Stein P.P., Kaufman K.D., Amatruda J.M. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int. J. Clin. Pract. 2010;64(5):562-76.
  15. Ahren B., Foley J.E., Ferrannini E., Matthews D.R., Zinman B., Dejager S., Fonseca V.A. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2010;33(4):730-32.
  16. Göke B., Gallwitz B., Eriksson J.G., Hellqvist A., Gause-Nilsson I. Saxagliptin vs. glipizide as addon therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int. J. Clin. Pract. 2013;67(4):307-16.
  17. GallwitzB.,RosenstockJ.,RauchT.,BhattacharyaS., Patel S., von Eynatten M., Dugi K.A., Woerle H.J. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet (London, England). 2012;380(9840):475-83.
  18. Ridderstrale M., Andersen K.R., Zeller C., Kim G., Woerle H.J., Broedl U.C. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(9):691-700.
  19. Nauck M.A., Del Prato S., Meier J.J., Duran-Garcia S., Rohwedder K., Elze M., Parikh S.J. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015-22.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies